Antisense Blocking of BRCA1 Enhances Sensitivity to Plumbagin but not Tamoxifen in BG-1 Ovarian Cancer Cells

Molecular Carcinogenesis

Volumn 39, Issue 1, 2004, Pages 15-25

  Srinivas, Gopal ^a   Annab, Lois A ^b   Gopinath, Gokul ^c   Banerji, Asoke ^d   Srinivas, Priya ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALICUT   (India)

^d REGIONAL RESEARCH LABORATORY CSIR   (India)

Author keywords

Apoptosis; BRCA1; Ovarian cancer; Plumbagin; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; DNA FRAGMENT; EMODIN; MESSENGER RNA; PLUMBAGIN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL NUCLEUS; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NITROBLUE TETRAZOLIUM TEST; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRCA1 PROTEIN; CELL DIVISION; EMODIN; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IN SITU NICK-END LABELING; MEMBRANE POTENTIALS; MITOCHONDRIA; NAPHTHOQUINONES; NEOPLASMS, HORMONE-DEPENDENT; OVARIAN NEOPLASMS; RNA, ANTISENSE; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0346727359     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10164     Document Type: Article

References (59)

1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
2. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-1462.
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
4. Marquis ST, Rajan JV, Wynshaw-Boris A, et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
5. Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298-302.
6. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 1995;9:2712-2722.
7. MacLachlan TK, Somasundaram K, Sgagias M, et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000;275:2777-2785.
8. 2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002;30:285-289.
9. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-586.
10. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000;275:33487-33496.
11. Lee EY. Tumor suppressor genes and their alterations in breast cancer. Semin Cancer Biol 1995;6:119-125.
12. Annab LA, Hawkins RE, Solomon G, Barrett JC, Afshari CA. Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line. Breast Cancer Res 2000;2:139-148.
13. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
14. Cohen I, Potlog-Nahari C, Shapira J, Yigael D, Tepper R. Simple ovarian cysts in postmenopausal patients with breast carcinoma treated with tamoxifen: Long-term follow-up. Radiology 2003;227:844-848.
15. Barnard DL, Huffman JH, Morris JL, Wood SG, Hughes BG, Sidwell RW. Evaluation of the antiviral activity of anthraquinones, anthrones, and anthraquinone derivatives against human cytomegalovirus. Antiviral Res 1992;17:63-77.
16. Lee HZ. Effects and mechanisms of emodin on cell death in human lung squamous cell carcinoma. Br J Pharmacol 2001;134:11-20.
17. Malterud KE, Farbrot TL, Huse AE, Sund RB. Antioxidant and radical scavenging effects of anthraquinones and anthrones. Pharmacology 1993;47(Suppl 1):77-85.
18. Muller SO, Eckert I, Lutz WK, Stopper H. Genotoxicity of the laxative drug components emodin, aloe-emodin, and danthron in mammalian cells: Topoisomerase II mediated? Mutat Res 1996;371:165-173.
19. Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML, Chu SH. Immunosuppressive effect of emodin, a free radical generator. Eur J Pharmacol 1992;211:359-364.
20. Kuo YC, Sun CM, Ou JC, Tsai WJ. A tumor cell growth inhibitor from Polygonum hypoleucum Ohwi. Life Sci 1997;61:2335-2344.
21. Zhang L, Chang CJ, Bacus SS, Hung MC. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 1995;55:3890-3896.
22. Srinivas G, Anto RJ, Srinivas P, Vidhyalakshmi S, Senan VP, Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol 2003;473:117-125.
23. Itoigawa M, Takeya K, Furukawa H. Cardiotonic action of plumbagin on guinea-pig papillary muscle. Planta Med 1991;57:317-319.
24. Premakumari P, Rathinam K, Santhakumari G. Antifertility activity of plumbagin. Indian J Med Res 1977;65:829-838.
25. Suzuki T, Ezure T, Ishida M. Synergistic effects of some pairs of antioxidants and related agents on mouse leukaemia L5178Y cell growth in-vitro. J Pharm Pharmacol 1998;50:1173-1177.
26. Imlay J, Fridovich I. Exogenous quinones directly inhibit the respiratory NADH dehydrogenase in Escherichia coli. Arch Biochem Biophys 1992;296:337-346.
27. Jaiswal AS, Bloom LB, Narayan S. Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: Involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1. Oncogene 2002;21:5912-5922.
28. Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998;16:1713-1721.
29. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-1356.
30. Shen SX, Weaver Z, Xu X, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998;17:3115-3124.
31. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999;274:18808-18812.
32. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a deft ned tumor cell line. Mol Cell 1999;4:1093-1099.
33. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120-1123.
34. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-23903.
35. Geisinger KR, Kute TE, Pettenati MJ, et al. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 1989;63:280-288.
36. Kamal GM, Gunaherath B, Leslie Gunatilaka AA, Uvais M, Sultanbawa S, Balasubramaniam S. 1,2(3)-Tetrahydro-3,3′-biplumbagin: A naphthalenone and other constituents from Plumbago zeylanica. Phytochemistry 1983;22:1245-1247.
37. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
38. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
39. Osin P, Gusterson BA, Philp E, et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998;34:1683-1686.
40. Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 2002;86:218-221.
41. Eisinger F, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Julian-Reynier C, Sobol H. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: Computed efficacy, effectiveness, and impact. Int J Oncol 2001;18:5-10.
42. Fan S, Ma YX, Wang C, et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001;20:77-87.
43. Fan S, Ma YX, Wang C, et al. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002;62:141-151.
44. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995;9:439.
45. Swisher E. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Curr Womens Health Rep 2003;3:27-32.
46. Baldwin WS, Curtis SW, Cauthen CA, Risinger JI, Korach KS, Barrett JC. BG-1 ovarian cell line: An alternative model for examining estrogen-dependent growth in vitro. In Vitro Cell Dev Biol Anim 1998;34:649-654.
47. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-477.
48. Matsuda H, Shimoda H, Morikawa T, Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): Structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg Med Chem Lett 2001;11:1839-1842.
49. Singh UV, Udupa N. Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Indian J Physiol Pharmacol 1997;41:171-175.
50. Kini DP, Pandey S, Shenoy BD, et al. Antitumor and antifertility activities of plumbagin controlled release formulations. Indian J Exp Biol 1997;35:374-379.
51. Naresh RA, Udupa N, Devi PU. Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol 1996;48:1128-1132.
52. Krishnaswamy M, Purushothaman KK. Plumbagin: A study of its anticancer, antibacterial, and antifungal properties. Indian J Exp Biol 1980;18:876-877.
53. Wang H, Mao Y, Chen AY, Zhou N, LaVoie EJ, Liu LF. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 2001;40:3316-3323.
54. Dietze EC, Caldwell LE, Grupin SL, Mancini M, Seewaldt VL. Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization. J Biol Chem 2001;276:5384-5394.
55. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-446.
56. Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): Key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002;115:4727-4734.
57. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001;410:549-554.
58. Loeffler M, Daugas E, Susin SA, et al. Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB J 2001;15:758-767.
59. Annab LA, Terry L, Cable PL, et al. Establishment and characterization of a breast cell strain containing a BRCA1 185delAG mutation. Gynecol Oncol 2000;77:121-128.